Takeda Pharmaceutical Company Limited (TAK) Balance Sheet
TAK balance sheet, FY2026
March 31, 2026 · Japanese yen¥15.52T assets = ¥7.71T liabilities + ¥7.81T equity
Both columns are drawn to the same scale: what TAK owns equals what it owes plus shareholders’ equity. Hover a block for its value.
TAK financial health
Current ratio1.27
Adequate · current assets cover current liabilities 1.27×
Debt / equity0.63
Moderate leverage · ¥0.63 of debt for each $1 of equity
Equity / assets50.3%
Equity-funded · of assets funded by shareholders
Cash / debt12.2%
Low cash cover · cash & short-term investments vs total debt
Goodwill & intangibles59.7%
Mostly intangible · of total assets
Descriptive bands, not a rating. Fiscal FY2026.
TAK balance sheet trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | ¥4.36TFY2017 | ¥15.52TFY2026 | +15.2%/yr | |
| Total liabilities | ¥2.41TFY2017 | ¥7.71TFY2026 | +13.8%/yr | |
| Shareholders’ equity | ¥1.89TFY2017 | ¥7.81TFY2026 | +17.0%/yr | |
| Cash & short-term investments | ¥376.14BFY2017 | ¥597.63BFY2026 | +5.3%/yr | |
| Total debt | ¥1.14TFY2017 | ¥4.90TFY2026 | +17.5%/yr | |
| Net cash (debt) | −¥768.75BFY2017 | −¥4.31TFY2026 | −¥3.5T | |
| Working capital | −¥105.43BFY2017 | ¥663.84BFY2026 | +¥769.3B | |
| Current ratio | 0.92FY2017 | 1.27FY2026 | +0.35 | |
| Debt / equity | 0.60FY2017 | 0.63FY2026 | +0.02 | |
| Shares outstanding | 1.57BFY2017 | 3.21BFY2026 | +8.2%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
TAK assets
Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current
TAK liabilities and equity
Current liabilitiesLong-term debtOther long-term liabilitiesEquity
TAK debt vs cash
Total debtCash & ST investmentsNet cash (debt)
Debt includes short- and long-term borrowings and, where reported, lease obligations.
TAK balance sheet in Japanese yen
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | ¥597.63B | ¥405.59B | ¥472.89B | ¥553.70B | ¥875.00B | ¥1.00T | ¥653.44B | ¥725.37B | ¥375.17B | ¥376.14B |
| Cash & equivalents | ¥597.63B | ¥385.11B | ¥457.80B | ¥533.53B | ¥849.70B | ¥966.22B | ¥637.61B | ¥702.09B | ¥294.52B | ¥319.45B |
| Short-term investments | ¥41.89B | ¥20.48B | ¥15.09B | ¥20.17B | ¥25.30B | ¥36.60B | ¥15.82B | ¥23.28B | ¥80.65B | ¥56.68B |
| Receivables | ¥880.15B | ¥725.25B | ¥697.61B | ¥681.69B | ¥724.38B | ¥812.71B | ¥784.92B | ¥749.12B | ¥428.79B | ¥444.78B |
| Inventory | ¥1.40T | ¥1.22T | ¥1.21T | ¥986.46B | ¥853.17B | ¥753.88B | ¥759.60B | ¥986.74B | ¥212.94B | ¥226.29B |
| Other current assets | ¥223.45B | ¥173.00B | ¥178.21B | ¥176.10B | ¥141.10B | ¥143.48B | ¥271.48B | ¥589.43B | ¥61.90B | ¥213.45B |
| Total current assets | ¥3.10T | ¥2.52T | ¥2.56T | ¥2.40T | ¥2.59T | ¥2.71T | ¥2.47T | ¥3.05T | ¥1.08T | ¥1.26T |
| Property, plant & equipment (net) | ¥2.13T | ¥1.97T | ¥1.99T | ¥1.69T | ¥1.58T | ¥1.45T | ¥1.39T | ¥1.32T | ¥536.80B | ¥530.15B |
| Goodwill & intangible assets | ¥9.27T | ¥8.96T | ¥9.68T | ¥9.06T | ¥8.23T | ¥7.94T | ¥8.18T | ¥9.02T | ¥2.04T | ¥2.09T |
| Long-term investments | ¥448.74B | ¥361.93B | ¥430.61B | ¥378.86B | ¥330.13B | ¥348.35B | ¥369.45B | ¥306.90B | ¥304.38B | ¥303.05B |
| Other non-current assets | ¥569.27B | ¥441.03B | ¥445.08B | ¥429.33B | ¥445.15B | ¥454.11B | ¥411.95B | ¥176.46B | ¥142.96B | ¥173.38B |
| Total assets | ¥15.52T | ¥14.25T | ¥15.11T | ¥13.96T | ¥13.18T | ¥12.91T | ¥12.82T | ¥13.87T | ¥4.11T | ¥4.36T |
| Liabilities | ||||||||||
| Accounts payable | ¥493.48B | ¥308.45B | ¥319.95B | ¥307.45B | ¥295.93B | ¥232.10B | ¥211.63B | ¥212.35B | ¥133.71B | ¥240.62B |
| Short-term debt | ¥514.38B | ¥548.94B | ¥367.25B | ¥339.60B | ¥203.99B | ¥22.15B | ¥586.82B | ¥984.95B | ¥18.0M | ¥545.03B |
| Deferred revenue | — | — | ¥109.91B | ¥740.74B | ¥644.42B | ¥616.48B | ¥587.98B | ¥627.26B | ¥200.47B | ¥206.38B |
| Total current liabilities | ¥2.44T | ¥2.51T | ¥2.31T | ¥2.48T | ¥2.15T | ¥1.77T | ¥2.18T | ¥2.51T | ¥737.51B | ¥1.37T |
| Long-term debt | ¥4.37T | ¥3.97T | ¥4.48T | ¥4.04T | ¥4.14T | ¥4.61T | ¥4.51T | ¥4.77T | ¥985.64B | ¥599.86B |
| Lease obligations | — | — | — | — | — | — | — | ¥0 | ¥0 | ¥0 |
| Other long-term liabilities | ¥901.87B | ¥839.52B | ¥1.05T | ¥1.08T | ¥1.21T | ¥1.35T | ¥1.41T | ¥1.43T | ¥365.90B | ¥440.86B |
| Total liabilities | ¥7.71T | ¥7.31T | ¥7.83T | ¥7.60T | ¥7.49T | ¥7.74T | ¥8.09T | ¥8.71T | ¥2.09T | ¥2.41T |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | ¥1.70T | ¥1.69T | ¥1.68T | ¥1.68T | ¥1.68T | ¥1.67T | ¥1.67T | ¥1.64T | ¥168.65B | ¥140.18B |
| Retained earnings (deficit) | ¥1.06T | ¥1.19T | ¥1.39T | ¥1.54T | ¥1.48T | ¥1.51T | ¥1.37T | ¥1.57T | ¥1.56T | ¥1.51T |
| Treasury stock | — | — | — | — | — | −¥59.55B | −¥87.46B | −¥57.14B | −¥74.37B | −¥48.73B |
| Accumulated other comprehensive income | ¥3.31T | ¥2.35T | ¥2.51T | ¥1.51T | ¥934.17B | ¥366.11B | ¥92.56B | ¥349.88B | −¥4.79B | ¥291.00B |
| Minority interest | ¥1.21B | ¥895.0M | ¥741.0M | ¥549.0M | — | — | — | ¥0 | ¥0 | ¥0 |
| Total shareholders' equity | ¥7.81T | ¥6.94T | ¥7.27T | ¥6.35T | ¥5.68T | ¥5.17T | ¥4.72T | ¥5.16T | ¥2.00T | ¥1.89T |
| Key figures | ||||||||||
| Total debt | ¥4.90T | ¥4.52T | ¥4.84T | ¥4.38T | ¥4.35T | ¥4.64T | ¥5.09T | ¥5.75T | ¥985.66B | ¥1.14T |
| Net cash (debt) | −¥4.31T | −¥4.11T | −¥4.37T | −¥3.83T | −¥3.47T | −¥3.63T | −¥4.44T | −¥5.03T | −¥610.49B | −¥768.75B |
| Working capital | ¥663.84B | ¥14.67B | ¥245.48B | −¥83.98B | ¥447.91B | ¥939.72B | ¥293.53B | ¥539.73B | ¥341.30B | −¥105.43B |
| Tangible book value | −¥1.46T | −¥2.02T | −¥2.41T | −¥2.71T | −¥2.54T | −¥2.77T | −¥3.46T | −¥3.86T | −¥46.09B | −¥194.28B |
| Shares outstanding | 3.21B | 3.21B | 3.16B | 3.14B | 3.15B | 3.15B | 3.13B | 1.93B | 1.57B | 1.57B |
| Current ratio | 1.27 | 1.01 | 1.11 | 0.97 | 1.21 | 1.53 | 1.13 | 1.21 | 1.46 | 0.92 |
| Quick ratio | 0.61 | 0.45 | 0.51 | 0.50 | 0.75 | 1.02 | 0.66 | 0.59 | 1.09 | 0.60 |
| Debt / equity | 0.63 | 0.65 | 0.67 | 0.69 | 0.76 | 0.90 | 1.08 | 1.11 | 0.49 | 0.60 |
| Equity / assets | 50.3% | 48.7% | 48.1% | 45.5% | 43.1% | 40.1% | 36.8% | 37.2% | 48.6% | 43.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | ¥527.58B | ¥597.63B | ¥761.94B | ¥739.68B | ¥419.18B | ¥405.59B | ¥526.75B | ¥906.22B | ¥857.66B | ¥472.89B | ¥317.40B | ¥333.81B |
| Cash & equivalents | ¥460.98B | ¥597.63B | ¥655.38B | ¥681.49B | ¥350.01B | ¥385.11B | ¥494.13B | ¥859.01B | ¥804.27B | ¥457.80B | ¥288.36B | ¥318.05B |
| Short-term investments | ¥66.60B | ¥41.89B | ¥107.00B | ¥58.19B | ¥69.17B | ¥20.48B | ¥32.62B | ¥47.20B | ¥53.39B | ¥15.09B | ¥29.05B | ¥15.76B |
| Receivables | ¥956.14B | ¥880.15B | ¥758.44B | ¥702.24B | ¥679.53B | ¥725.25B | ¥735.06B | ¥721.06B | ¥772.37B | ¥697.61B | ¥743.08B | ¥788.07B |
| Inventory | ¥1.45T | ¥1.40T | ¥1.41T | ¥1.30T | ¥1.24T | ¥1.22T | ¥1.25T | ¥1.21T | ¥1.28T | ¥1.21T | ¥1.17T | ¥1.16T |
| Other current assets | ¥219.29B | ¥223.45B | ¥190.03B | ¥179.22B | ¥173.74B | ¥173.00B | ¥246.05B | ¥220.31B | ¥200.77B | ¥178.21B | ¥198.71B | ¥184.33B |
| Total current assets | ¥3.15T | ¥3.10T | ¥3.12T | ¥2.92T | ¥2.51T | ¥2.52T | ¥2.75T | ¥3.05T | ¥3.11T | ¥2.56T | ¥2.43T | ¥2.46T |
| Property, plant & equipment (net) | ¥2.14T | ¥2.13T | ¥2.09T | ¥1.98T | ¥1.96T | ¥1.97T | ¥2.02T | ¥1.89T | ¥2.09T | ¥1.99T | ¥1.84T | ¥1.89T |
| Goodwill & intangible assets | ¥9.28T | ¥9.27T | ¥9.28T | ¥8.73T | ¥8.72T | ¥8.96T | ¥9.47T | ¥8.93T | ¥10.10T | ¥9.68T | ¥9.21T | ¥9.70T |
| Long-term investments | ¥473.22B | ¥448.74B | ¥434.17B | ¥374.33B | ¥347.12B | ¥361.93B | ¥410.21B | ¥277.31B | ¥447.18B | ¥430.61B | ¥372.92B | ¥416.36B |
| Other non-current assets | ¥619.45B | ¥569.27B | ¥505.93B | ¥460.30B | ¥469.61B | ¥441.03B | ¥450.42B | ¥423.32B | ¥487.73B | ¥445.08B | ¥371.39B | ¥395.88B |
| Total assets | ¥15.66T | ¥15.52T | ¥15.42T | ¥14.47T | ¥14.00T | ¥14.25T | ¥15.11T | ¥14.57T | ¥16.23T | ¥15.11T | ¥14.22T | ¥14.87T |
| Liabilities | ||||||||||||
| Accounts payable | ¥446.78B | ¥493.48B | ¥467.91B | ¥438.99B | ¥421.31B | ¥308.45B | ¥460.18B | ¥413.33B | ¥468.88B | ¥319.95B | ¥483.67B | ¥421.08B |
| Short-term debt | ¥519.97B | ¥514.38B | ¥583.55B | ¥293.86B | ¥371.14B | ¥548.94B | ¥135.47B | ¥624.10B | ¥438.74B | ¥367.25B | ¥370.29B | ¥274.84B |
| Deferred revenue | — | — | — | — | — | — | — | — | ¥162.20B | ¥109.91B | ¥594.91B | ¥787.88B |
| Total current liabilities | ¥2.76T | ¥2.44T | ¥2.61T | ¥2.14T | ¥2.17T | ¥2.51T | ¥2.10T | ¥2.39T | ¥2.47T | ¥2.31T | ¥2.28T | ¥2.37T |
| Long-term debt | ¥4.42T | ¥4.37T | ¥4.27T | ¥4.35T | ¥4.13T | ¥3.97T | ¥4.70T | ¥4.43T | ¥5.04T | ¥4.48T | ¥4.29T | ¥4.40T |
| Other long-term liabilities | ¥919.85B | ¥901.87B | ¥887.84B | ¥847.49B | ¥833.97B | ¥839.52B | ¥885.01B | ¥837.07B | ¥921.01B | ¥1.05T | ¥904.30B | ¥1.03T |
| Total liabilities | ¥8.10T | ¥7.71T | ¥7.77T | ¥7.34T | ¥7.14T | ¥7.31T | ¥7.69T | ¥7.65T | ¥8.43T | ¥7.83T | ¥7.48T | ¥7.80T |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | ¥1.70T | ¥1.70T | ¥1.70T | ¥1.69T | ¥1.69T | ¥1.69T | ¥1.69T | ¥1.69T | ¥1.68T | ¥1.68T | ¥1.68T | ¥1.68T |
| Retained earnings (deficit) | ¥667.01B | ¥1.06T | ¥1.10T | ¥1.15T | ¥1.16T | ¥1.19T | ¥1.29T | ¥1.43T | ¥1.34T | ¥1.39T | ¥1.40T | ¥1.45T |
| Accumulated other comprehensive income | −¥11.05B | ¥3.31T | ¥3.15T | −¥3.60B | ¥2.35T | ¥2.35T | ¥2.70T | ¥2.08T | ¥3.08T | ¥2.51T | ¥1.99T | ¥2.29T |
| Minority interest | ¥989.0M | ¥1.21B | ¥1.15B | ¥992.0M | ¥921.0M | — | — | — | — | — | — | — |
| Total shareholders' equity | ¥7.56T | ¥7.81T | ¥7.65T | ¥7.13T | ¥6.87T | ¥6.94T | ¥7.42T | ¥6.92T | ¥7.80T | ¥7.27T | ¥6.74T | ¥7.07T |
| Key figures | ||||||||||||
| Total debt | ¥4.94T | ¥4.90T | ¥4.86T | ¥4.65T | ¥4.51T | ¥4.52T | ¥4.84T | ¥5.05T | ¥5.48T | ¥4.84T | ¥4.66T | ¥4.68T |
| Net cash (debt) | −¥4.41T | −¥4.31T | −¥4.09T | −¥3.91T | −¥4.09T | −¥4.11T | −¥4.31T | −¥4.14T | −¥4.62T | −¥4.37T | −¥4.35T | −¥4.35T |
| Working capital | ¥385.72B | ¥663.84B | ¥506.60B | ¥780.97B | ¥343.54B | ¥14.67B | ¥656.32B | ¥666.78B | ¥642.33B | ¥245.48B | ¥146.66B | ¥94.45B |
| Tangible book value | −¥1.72T | −¥1.46T | −¥1.63T | −¥1.60T | −¥1.85T | −¥2.02T | −¥2.06T | −¥2.01T | −¥2.30T | −¥2.41T | −¥2.47T | −¥2.63T |
| Shares outstanding | 3.21B | 3.12B | 3.20B | 3.15B | 3.18B | 3.16B | 3.17B | 3.22B | 3.18B | 3.14B | 3.17B | 3.13B |
| Current ratio | 1.14 | 1.27 | 1.19 | 1.36 | 1.16 | 1.01 | 1.31 | 1.28 | 1.26 | 1.11 | 1.06 | 1.04 |
| Quick ratio | 0.54 | 0.61 | 0.58 | 0.67 | 0.51 | 0.45 | 0.60 | 0.68 | 0.66 | 0.51 | 0.46 | 0.47 |
| Debt / equity | 0.65 | 0.63 | 0.64 | 0.65 | 0.66 | 0.65 | 0.65 | 0.73 | 0.70 | 0.67 | 0.69 | 0.66 |
| Equity / assets | 48.3% | 50.3% | 49.6% | 49.3% | 49.0% | 48.7% | 49.1% | 47.5% | 48.1% | 48.1% | 47.4% | 47.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in Japanese yen as reported (latest annual report filed June 17, 2026); data from EODHD.
TAK financial position
At the end of fiscal 2026 (March 31, 2026), Takeda Pharmaceutical had total assets of ¥15.52 trillion (up 8.9% from a year earlier), total liabilities of ¥7.71 trillion and shareholders' equity of ¥7.81 trillion. It held ¥597.6 billion in cash and short-term investments against ¥4.90 trillion of debt, net debt of ¥4.31 trillion. Its current ratio was 1.27. In the latest quarter (ended June 30, 2026) total assets were ¥15.66 trillion and equity ¥7.56 trillion.
Related: TAK income statement, TAK cash flow statement, TAK key metrics. See the TAK stock overview for the latest quote and news.
TAK balance sheet FAQ
What are Takeda Pharmaceutical's total assets?
Takeda Pharmaceutical reported total assets of ¥15.52 trillion at the end of fiscal 2026 (March 31, 2026), compared with ¥14.25 trillion a year earlier.
How much debt does Takeda Pharmaceutical have?
Takeda Pharmaceutical had ¥4.90 trillion of total debt at the end of fiscal 2026, including short-term borrowings. Its debt-to-equity ratio was 0.63.
How much cash does Takeda Pharmaceutical have?
Takeda Pharmaceutical held ¥597.6 billion in cash and short-term investments at the end of fiscal 2026; with ¥4.90 trillion of debt that is net debt of ¥4.31 trillion.
What is Takeda Pharmaceutical's book value?
Takeda Pharmaceutical's shareholders' equity (book value) was ¥7.81 trillion at the end of fiscal 2026.
What is Takeda Pharmaceutical's current ratio?
Takeda Pharmaceutical had current assets of ¥3.10 trillion and current liabilities of ¥2.44 trillion, a current ratio of 1.27 (it can cover its short-term obligations).
How much goodwill does Takeda Pharmaceutical have?
Takeda Pharmaceutical carried ¥9.27 trillion of goodwill and intangible assets, 59.7% of total assets, at the end of fiscal 2026.